Our Approach

Satellite Bio is the first company to establish proprietary protocols that allow us to effectively isolate, expand and mature primary hepatocyte cells in-house. This cutting-edge process yields mature cells capable of effective engraftment and functions as primary hepatocytes in vivo.

From a single liver, we can produce enough cells to potentially treat thousands of individuals with advanced liver disease.

We’ve pioneered the creation of Tissue Seeds, which are heterocellular aggregates comprised of our expanded hepatocytes and supportive cells. This precise blend enables optimal engraftment and function of the hepatocyte outside of the liver. By engineering this microenvironment, our Tissue Seeds ensure the survival and functionality of the hepatocytes, as validated across various animal models.

Satellite Bio’s team of experts has optimized the production, formulation and cryopreservation of our cell-based therapies, with a scalable, xeno-free, cost-effective and cGMP-compliant process that produces stable, cryopreserved drug products. This proprietary approach enables a far-reaching distribution of the stable drug product from a centralized manufacturing facility. Satellite Bio’s products are truly off-the-shelf advanced therapies, but with the practicality and cost profile of a traditional drug. 

Key achievements include:

-Liver isolation

-Hepatocyte expansion

-Comprehensive release testing

-Robust cryopreservation methods